Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,281.43 +380.88 (+0.60%) CMC Crypto 200
1,347.87 -12.46 (-0.92%)
RPTX Jan 2025 5.000 call
| Previous close | 0.6900 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 5.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.6900 - 0.6900 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
- Business Wire
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
CAMBRIDGE, Mass. & MONTREAL, June 10, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial.
ZacksRepare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.
- Business Wire
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
CAMBRIDGE, Mass. & MONTREAL, June 04, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lunresertib in combination with camonsertib for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer.
